Want to see AU:CTE full AI Analyst Report?
Cryosite Limited (CTE) AI Stock Analysis
Cryosite Limited
(ASX:CTE)
The overall score of 67 (Financials: 50%, Technicals: 30%, Valuation: 20%) is driven by a strong technical uptrend and solid top-line revenue growth. These strengths are partially offset by a moderate valuation and increased financial risk stemming from rising debt and negative free cash flow.
Cryosite Limited (CTE) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 59.55M
- Dividend Yield
- ―
- Average Volume (3M)
- 5,923
- Price to Earnings (P/E)
- 26.6
- Beta (1Y)
- -0.10
- Revenue Growth
- 18.31%
- EPS Growth
- 18.65%
- Country
- Australia
- Employees
- 27
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Cryosite Limited Business Overview & Revenue Model
Company Description
Cryosite Limited, founded in 1999 and headquartered in South Granville, Australia, specializes in providing outsourced logistics and storage solutions to the life sciences industry within Australia. The company operates through two distinct divisions...
How the Company Makes Money
null
Cryosite Limited Financial Statement Overview
Summary
Strong operational execution with consistent revenue and earnings growth is offset by rising financial leverage and heavily negative free cash flow due to significant capital expenditures.
Income Statement
85Very PositiveBalance Sheet
65PositiveCash Flow
45Neutral| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.70M | 16.70M | 14.12M | 12.61M | 11.94M | 11.76M |
| Gross Profit | 9.51M | 9.51M | 8.89M | 7.99M | 6.48M | 6.27M |
| EBITDA | 3.99M | 4.07M | 3.41M | 3.04M | 2.30M | 2.40M |
| Net Income | 2.23M | 2.23M | 1.88M | 1.84M | 1.41M | 1.36M |
Balance Sheet | ||||||
| Total Assets | 25.97M | 25.97M | 19.46M | 19.71M | 22.65M | 21.50M |
| Cash, Cash Equivalents and Short-Term Investments | 2.24M | 2.24M | 5.06M | 4.70M | 5.73M | 5.34M |
| Total Debt | 7.72M | 7.72M | 2.27M | 2.44M | 2.61M | 849.76K |
| Total Liabilities | 21.12M | 21.12M | 17.07M | 18.26M | 19.86M | 19.64M |
| Stockholders Equity | 4.85M | 4.85M | 2.39M | 1.45M | 2.78M | 1.86M |
Cash Flow | ||||||
| Free Cash Flow | -8.14M | -8.14M | 1.48M | 2.44M | 1.19M | 1.63M |
| Operating Cash Flow | 2.73M | 2.73M | 2.06M | 2.90M | 1.49M | 2.49M |
| Investing Cash Flow | -10.87M | -10.87M | -420.00K | 727.00K | -1.33M | -863.19K |
| Financing Cash Flow | 5.33M | 5.33M | -1.29M | -3.50M | -768.00K | -148.99K |
Cryosite Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTE, the sentiment is Positive. The current price of 1.22 is above the 20-day moving average (MA) of 1.20, above the 50-day MA of 1.20, and above the 200-day MA of 1.16, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 55.81 is Neutral, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CTE.
Cryosite Limited Peers Comparison
Overall Rating
AU:SHL72Outperform- AU:CTE67Neutral
AU:ACL60Neutral
AU:MVF53Neutral
AU:HLS51Neutral
AU:GSS39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:SHL | 72Outperform | AUD 9.67B | 15.91 | 7.20% | 5.52% | 14.40% | 15.11% |
| AU:CTE | 67Neutral | AUD 59.55M | 26.64 | 52.84% | ― | 18.31% | 18.65% |
| AU:ACL | 60Neutral | AUD 615.51M | 26.70 | 15.80% | 3.94% | -0.90% | -25.09% |
| AU:MVF | 53Neutral | AUD 280.54M | 37.70 | 2.95% | 3.47% | -0.90% | -70.25% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:HLS | 51Neutral | AUD 359.46M | -0.86 | -114.08% | ― | 2.16% | 21.05% |
| AU:GSS | 39Underperform | AUD 17.72M | -1.27 | -35.10% | ― | -9.10% | 31.75% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:CTE | Cryosite Limited | 1.22 | 0.02 | 1.67% | |
| AU:HLS | Healius Limited | 0.49 | -0.39 | -44.07% | |
| AU:GSS | Genetic Signatures Ltd. | 0.08 | -0.22 | -73.56% | |
| AU:SHL | Sonic Healthcare Limited | 19.57 | -0.30 | -1.52% | |
| AU:ACL | Australian Clinical Labs Ltd | 3.30 | 0.80 | 32.11% | |
| AU:MVF | Monash IVF Group Ltd | 0.72 | 0.05 | 8.11% |
Cryosite Limited Corporate Events
Cryosite doubles storage footprint and posts record FY26 results
Cryosite Limited has more than doubled its storage and warehousing footprint to over 4,200 square metres after acquiring a second freehold facility in Auburn and extending its principal cool room at its South Granville headquarters. The company aims...
Cryosite files 2026 corporate governance statement and ASX Appendix 4G
Cryosite Limited has lodged its corporate governance statement for the year ended 30 June 2026 with the ASX and published it on its website, detailing how it adheres to the ASX Corporate Governance Council’s principles and recommendations. The...
Cryosite boosts profit and doubles storage capacity as it withholds dividend
Cryosite Limited reported a strong improvement in trading conditions for the year ended 30 June 2026, with revenue rising 18% to $16.7 million and net profit after tax increasing 19% to $2.24 million. Key profitability metrics also advanced, as EBITD...
Cryosite lifts profit on higher utilisation and prepares for next growth phase
Cryosite reported unaudited FY2026 revenue of $16.7 million, up 18%, with EBITDA rising 27% to $4.3 million and margins expanding as utilisation of its Ferndell Street headquarters improved. Net profit after tax increased 20% to $2.3 million, with ea...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026